The system is in place to do that already. It's working in a very healthy way. On the small molecule side, you have the patent protection that allows the generics to come in. We're moving to the same sort of system for the complex biologics. That's already there.
In a pharmacare system, I think the challenge is going to be—and you were pointing this out in your remarks—that if you move uniquely to one type, whether it's a generic or you limit access to a number of different innovative medicines, you're creating a marketplace that's not competitive with other marketplaces. We're talking about a global marketplace. It's nice to think of Canada as a nice, comfortable place to be, but we're actually in a global marketplace.
Similarly, you can't go to Fort McMurray and get gas for 10¢ a litre. The reason for that is you buy gas in the global marketplace. This is not dissimilar. It's even more complex because we're not a commodity. We're an innovative product.
If you look at the therapy as a commodity and treat it as such, you will have negative implications for the innovative side writ large.